It’s time to let scientists study whether LSD, marijuana and ecstasy can ease psychiatric disorders
Discovery of new psychiatric medication, whether for the treatment of depression, autism or schizophrenia, is at a virtual standstill. As just one example, the antidepressants on the market today are no more effective at reversing the mood disorder than those that first became available in the 1950s.
New thinking is desperately needed to aid the estimated 14 million American adults who suffer from severe mental illness. Innovation would likely accelerate if pharmacologists did not have to confront an antiquated legal framework that, in effect, declares off-limits a set of familiar compounds that could potentially serve as the chemical basis for entire new classes of drugs.
LSD, ecstasy (MDMA), psilocybin and marijuana have, for decades, been designated as drugs of abuse. But they had their origins in the medical pharmacopeia. Through the mid-1960s, more than 1,000 scientific publications chronicled the ways that LSD could be used as an aid to make psychotherapy more effective. Similarly, MDMA began to be used as a complement to talk therapy in the 1970s. Marijuana has logged thousands of years as a medicament for diseases and conditions ranging from malaria to rheumatism.
National laws and international conventions put a stop to all that. The Controlled Substances Act of 1970 declared that these drugs have “no currently accepted medical use” and classified them in the most stringently regulated category of controlled substances: Schedule I. The resulting restrictions create a de facto ban on their use in both laboratories and clinical trials, setting up a catch-22: these drugs are banned because they have no accepted medical use, but researchers cannot explore their therapeutic potential because they are banned. Three United Nations treaties extend similar restrictions to much of the rest of the world.
The decades-long research hiatus has taken its toll. Psychologists would like to know whether MDMA can help with intractable post-traumatic stress disorder, whether LSD or psilocybin can provide relief for cluster headaches or obsessive-compulsive disorder, and whether the particular docking receptors on brain cells that many psychedelics latch onto are critical sites for regulating conscious states that go awry in schizophrenia and depression.
The Latest on: Psychoactive Drug Research
[google_news title=”” keyword=”Psychoactive Drug Research” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Psychoactive Drug Research
- Mitch McConnell's Cannabis Gambit: How The Farm Bill Unwittingly Fueled A THC Boomon May 12, 2024 at 9:50 am
There is no shortage of unintended legislative consequences in the brief history of legal cannabis, but the 2018 Agricultural Improvement Act—popularly known as the Farm Bill —may take the cake. Most ...
- Drugs, Sacraments or Medicine? Psychedelic Churches Blur the Line.on May 12, 2024 at 2:01 am
Organizations that describe themselves as churches are providing psychedelics to followers. The compounds, which show promise as treatments for depression, are illegal in most settings.
- How long does marijuana THC linger in breast milk for new moms? What new study foundon May 10, 2024 at 3:22 pm
Breastfeeding mothers who use cannabis may be transferring THC to their babies, researchers found. The study, published May 2 in the journal Breastfeeding Medicine found that THC, the psychoactive ...
- Montgomery County Residents: THC Lingers in Breastmilk for Days. Doctor Explainson May 10, 2024 at 10:46 am
In this article, Dr. Adriana Davis, Family Medicine, shares her expert insights of the findings and provides Virginia residents with evidence-based recommendations for protecting their health.Why This ...
- Drugs News and Researchon May 7, 2024 at 5:00 pm
When breastfeeding mothers in a recent study used cannabis, its psychoactive component ... of hyper accurate cancer drugs is in production at a newly opened research and manufacturing hub at ...
- ‘Behind the 8 Ball’: Research is trying to catch up on cannabis and kidson May 4, 2024 at 3:29 pm
Despite health risks, delta-8-THC is widely considered to be legal at the federal level. Concerns are compounded by the fact that it can be found in kid-friendly products, like gummies and chocolates, ...
- Understanding THC: The primary psychoactive compound in cannabison May 3, 2024 at 7:04 pm
Hey friends! 🌿🔬 Curious about cannabis and its compounds? 🌱 Check out this fascinating article that breaks down THC, CBD, Delta-9, Delta-10, and marijuana. 🌿🔥 Learn about their effects, ...
- Mechanisms of Actionon May 3, 2024 at 5:01 pm
It said, "One kick, $1. Knowing where to kick, $9999." One way to understand the effects of psychotropic drugs in general and serotonergic drugs in particular is to see them as well placed kicks ...
- New Research Power Ups Psilocybin’s Potential as an Antidepressanton May 2, 2024 at 6:45 pm
A team of researchers sought to determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs.
- SUFARI – a substance use tool for mental health serviceson April 16, 2024 at 3:07 am
To improve the tools used for reporting and recording this information. To recognise trends such as increasing use of novel psychoactive drugs. CNWL’s Dual Diagnosis policy covers the assessment of ...
via Bing News